{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T07:11:12Z","timestamp":1724310672601},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10067-020-05217-x","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:03:14Z","timestamp":1591682594000},"page":"205-211","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease"],"prefix":"10.1007","volume":"40","author":[{"given":"Itthiphat","family":"Arunsurat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajanee","family":"Mahakkanukrauh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chingching","family":"Foocharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siraphop","family":"Suwannaroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratanavadee","family":"Nanagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the scleroderma research group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"2","key":"5217_CR1","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202\u2013205","journal-title":"J Rheumatol"},{"issue":"10","key":"5217_CR2","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/1756-185X.13060","volume":"20","author":"C Foocharoen","year":"2017","unstructured":"Foocharoen C, Watcharenwong P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2017) Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais. Int J Rheum Dis 20(10):1572\u20131581","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"5217_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3109\/14397595.2015.1115455","volume":"26","author":"S Wangkaew","year":"2016","unstructured":"Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W (2016) Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol 26(4):588\u2013593","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5217_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V (2015) \u201cERS\/ATS task force on undifferentiated forms of CTD-ILD\u201d. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46(4):976\u2013987","journal-title":"Eur Respir J"},{"issue":"11","key":"5217_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248\u20131254","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"5217_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"5","key":"5217_CR7","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10(5):R124","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5217_CR8","first-page":"313","volume":"34","author":"T Wagner","year":"1984","unstructured":"Wagner T, Fenneberg K (1984) Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung. 34(3):313\u2013316","journal-title":"Arzneimittelforschung."},{"issue":"6","key":"5217_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1056\/NEJM197508072930604","volume":"293","author":"RL Wall","year":"1975","unstructured":"Wall RL, Clausen KP (1975) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med 293(6):271\u2013273","journal-title":"N Engl J Med"},{"issue":"10","key":"5217_CR10","first-page":"2313","volume":"4","author":"H Payne","year":"1998","unstructured":"Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C, Huddart R, McMenemin R, Patel P, Peters JL, Thompson A, Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP (1998) Similar bioavailability of single-dose oral and intravenous Mesna in the blood and urine of healthy human subjects. Clin Cancer Res 4(10):2313\u20132320","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5217_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s100670050138","volume":"18","author":"EM Davas","year":"1999","unstructured":"Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18(6):455\u2013461","journal-title":"Clin Rheumatol"},{"key":"5217_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2369-11-12","volume":"11","author":"GD Walters","year":"2010","unstructured":"Walters GD, Willis NS, Craig JC (2010) Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 11:12","journal-title":"BMC Nephrol"},{"issue":"6","key":"5217_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D (2012) EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6):955\u2013960","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5217_CR14","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011 Feb 15) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"20","key":"5217_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30(20):2493\u20132537","journal-title":"Eur Heart J"},{"issue":"6","key":"5217_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1164\/rccm.200403-331OC","volume":"171","author":"Y Jegal","year":"2005","unstructured":"Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, Kitaichi M, Colby TV (2005) Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171(6):639\u2013644","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"5217_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jep.12629","volume":"23","author":"R Bohannon","year":"2017","unstructured":"Bohannon R, Crouch R (2017) Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review: systematic review of MCID in 6MWT. J Eval Clin Pract 23(2):377\u2013381","journal-title":"J Eval Clin Pract"},{"issue":"2 Suppl 65","key":"5217_CR18","first-page":"S53","volume":"29","author":"K Deuschle","year":"2011","unstructured":"Deuschle K, Weinert K, Becker MO, Backhaus M, Huscher D, Riemekasten G (2011) Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):S53\u2013S59","journal-title":"Clin Exp Rheumatol"},{"issue":"25","key":"5217_CR19","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666","journal-title":"N Engl J Med"},{"issue":"12","key":"5217_CR20","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962\u20133970","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5217_CR21","first-page":"1064","volume":"35","author":"A B\u00e9rezn\u00e9","year":"2008","unstructured":"B\u00e9rezn\u00e9 A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35(6):1064\u20131072","journal-title":"J Rheumatol"},{"issue":"4","key":"5217_CR22","first-page":"731","volume":"29","author":"R Giacomelli","year":"2002","unstructured":"Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29(4):731\u2013736","journal-title":"J Rheumatol"},{"issue":"1","key":"5217_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1183\/09031936.00060209","volume":"35","author":"M Gilson","year":"2010","unstructured":"Gilson M, Zerkak D, Wipff J, Dusser D, Dinh-Xuan AT, Abitbol V, Chaussade S, Legmann P, Kahan A, Allanore Y (2010) Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 35(1):112\u2013117","journal-title":"Eur Respir J"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05217-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05217-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05217-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T19:49:40Z","timestamp":1623181780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05217-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5217"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05217-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"5 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This research was approved by the Human Research Ethics Committee of Khon Kaen University (HE611252)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}